

**Applicant:** Jubilant Pharma SA (Pty) Ltd.

MODULE 1

**Product Name:**

**Dosage form and strength:**

1.3.1.1

SILDOJUB 25 mg

Each film coated tablet contains sildenafil citrate equivalent to 25 mg sildenafil

SILDOJUB 50 mg

Each film coated tablet contains sildenafil citrate equivalent to 50 mg sildenafil

SILDOJUB 100 mg

Each film coated tablet contains sildenafil citrate equivalent to 100 mg sildenafil

**Amendment date:** 12 May 2025

### 1.3.1.1 Clean proposed professional information

The clean proposed professional information follows on page 2.

Sign:



1.3.1.1  
12/May/2025

Page 1 of 17

**Applicant:** Jubilant Pharma SA (Pty) Ltd.

MODULE 1

**Product Name:**

1.3.1.1

SILDOJUB 25 mg

**Dosage form and strength:**

Each film coated tablet contains sildenafil citrate equivalent to 25 mg sildenafil

SILDOJUB 50 mg

Each film coated tablet contains sildenafil citrate equivalent to 50 mg sildenafil

SILDOJUB 100 mg

Each film coated tablet contains sildenafil citrate equivalent to 100 mg sildenafil

**Amendment date:** 12 May 2025

## SCHEDULING STATUS

S4

### 1. NAME OF THE MEDICINE

**Sildojub 25 mg** (film coated tablets)

**Sildojub 50 mg** (film coated tablets)

**Sildojub 100 mg** (film coated tablets)

### 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

**Sildojub 25 mg:** Each film coated tablet contains sildenafil citrate equivalent to 25 mg sildenafil.

**Sildojub 50 mg:** Each film coated tablet contains sildenafil citrate equivalent to 50 mg sildenafil.

**Sildojub 100 mg:** Each film coated tablet contains sildenafil citrate equivalent to 100 mg sildenafil.

### 3. PHARMACEUTICAL FORM


**Sildojub 25 mg:** White, oval shaped, biconvex, film coated tablets, plain on one side and debossed with 'B9' on the other side.

**Sildojub 50 mg:** White, oval shaped, biconvex, film coated tablets, plain on one side and debossed with 'C1' on the other side.

**Sildojub 100 mg:** White, oval shaped, biconvex, film coated tablets, plain on one side and debossed with '436' on the other side.

### 4. CLINICAL PARTICULARS

#### 4.1 Therapeutic indications

Sign: 

1.3.1.1  
12/May/2025

Page 2 of 17

**Applicant:** Jubilant Pharma SA (Pty) Ltd.

MODULE 1

**Product Name:**

1.3.1.1

SILDOJUB 25 mg

**Dosage form and strength:**

Each film coated tablet contains sildenafil citrate equivalent to 25 mg sildenafil

SILDOJUB 50 mg

Each film coated tablet contains sildenafil citrate equivalent to 50 mg sildenafil

SILDOJUB 100 mg

Each film coated tablet contains sildenafil citrate equivalent to 100 mg sildenafil

**Amendment date:** 12 May 2025

**Sildojub** is indicated only for the treatment of erectile dysfunction.

**SILDOJUB IS NOT AN APHRODISIAC.**

#### 4.2 Posology and method of administration

**Adults:**

The recommended oral dose is 50 mg, taken as needed once daily, approximately one hour before sexual intercourse. The dose may be increased to 100 mg or decreased to 25 mg, depending on the efficacy and tolerance. The maximum recommended dose is 100 mg. The maximum recommended dosing frequency is once daily.

**Elderly and patients with impaired renal or hepatic function:**

In patients with reduced clearance, increased **Sildojub** plasma levels and an increase in the incidence of adverse events may occur. A starting dose of 25 mg should be considered.


**Sildojub** administration is contraindicated in patients who use nitric oxide donors or nitrates in any form, as it was shown to potentiate the hypotensive effects of nitrates (see Section 4.3).

**Children:**

**Sildojub** is not indicated for use in children.

#### 4.3 Contraindications

- Known hypersensitivity to sildenafil or to any of the other components of **Sildojub** (see **Section 2)**.

Sign: 

1.3.1.1  
12/May/2025

Page 3 of 17

**Product Name:**

**Dosage form and strength:**

SILDOJUB 25 mg

Each film coated tablet contains sildenafil citrate equivalent to 25 mg sildenafil

SILDOJUB 50 mg

Each film coated tablet contains sildenafil citrate equivalent to 50 mg sildenafil

SILDOJUB 100 mg

Each film coated tablet contains sildenafil citrate equivalent to 100 mg sildenafil


**Amendment date:** 12 May 2025

- Consistent with its known effects on the nitric oxide/cGMP pathway (**see section 5**), sildenafil was shown to potentiate the hypotensive effects of acute and chronic nitrates, and its co-administration with nitric oxide donors or nitrates in any form, either regularly or intermittently, is therefore contraindicated. Doctors should discuss the contraindication of **Sildojub** with concurrent organic nitrates.
- Severe hepatic impairment (e.g. cirrhosis).
- Severe renal impairment (e.g. creatinine clearance < 30 ml/min).
- Concomitant use of **Sildojub** with potent cytochrome P450 3A4 inhibitors (e.g. cimetidine, erythromycin, ritonavir, saquinavir, ketoconazole, itraconazole) is contraindicated (see Section 4.5).

#### 4.4 Special warnings and precautions for use

**There is a potential of cardiac risk with sexual activity in patients with pre-existing cardiovascular disease. Therefore, treatments for erectile dysfunction, including Sildojub, should generally not be used in men for whom sexual activity is inadvisable because of their underlying cardiovascular status.**

- A thorough medical history and physical examination should be undertaken to diagnose erectile dysfunction, determine potential underlying causes, and identify appropriate treatment.
- **Sildojub** has systemic vasodilatory properties that resulted in transient decrease in supine blood pressure in healthy volunteers. Medical practitioners should carefully consider whether their patients with underlying cardiovascular disease could be affected adversely by such vasodilatory effects, especially in combination with sexual activity.

Sign: 

**Product Name:**

**Dosage form and strength:**

1.3.1.1

SILDOJUB 25 mg

Each film coated tablet contains sildenafil citrate equivalent to 25 mg sildenafil

SILDOJUB 50 mg

Each film coated tablet contains sildenafil citrate equivalent to 50 mg sildenafil

SILDOJUB 100 mg

Each film coated tablet contains sildenafil citrate equivalent to 100 mg sildenafil

**Amendment date:** 12 May 2025

- Patients with increased susceptibility to vasodilators include those with left ventricular outflow obstruction (such as aortic stenosis or hypertrophic obstructive cardiomyopathy), or those with the syndrome of multiple system atrophy manifesting as severely impaired autonomic control of blood pressure.
- Concomitant administration of **Sildojub** to patients taking alpha-blocker therapy may lead to symptomatic hypotension in susceptible individuals (**see section 4.5**). In order to minimise the potential for developing postural hypotension, patients should be haemodynamically stable on alpha-blocker therapy prior to initiating **Sildojub** treatment. Doctors should advise patients what to do in the event of postural hypotensive symptoms.
- **Sildojub** should be prescribed with caution in the following patients:
  - Patients who have suffered a myocardial infarction, stroke or life-threatening dysrhythmia within the last 6 months.
  - Patients with resting hypotension (BP < 90/50) or hypertension (BP > 170/110).
  - Patients with cardiac failure or coronary artery disease, causing unstable angina.
  - Patients with retinitis pigmentosa (a minority of these patients have genetic disorders of retinal phosphodiesterases).
- Patients should seek immediate medical assistance in the event of an erection that persists longer than 4 hours. Priapism (painful erections lasting longer than 6 hours) should be treated immediately, as penile tissue damage and permanent loss of potency could result.
- **Sildojub** should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie's disease) or in patients who have conditions which may predispose them to priapism (such as sickle cell anaemia, multiple myeloma or leukaemia).

**Applicant:** Jubilant Pharma SA (Pty) Ltd.

MODULE 1

**Product Name:**

SILDOJUB 25 mg

SILDOJUB 50 mg

SILDOJUB 100 mg

**Dosage form and strength:**

Each film coated tablet contains sildenafil citrate equivalent to 25 mg sildenafil

Each film coated tablet contains sildenafil citrate equivalent to 50 mg sildenafil

Each film coated tablet contains sildenafil citrate equivalent to 100 mg sildenafil

1.3.1.1

**Amendment date:** 12 May 2025

- Combinations of **Sildojub** with other treatments for erectile dysfunction is not recommended as the safety and efficacy of such combinations have not been studied.
- **Sildojub** should be administered with caution to patients with bleeding disorders or active peptic ulceration.
- **Sildojub** has no effect on bleeding time, including during co-administration with aspirin.
- Non-arteritic anterior ischaemic optic neuropathy (NAION) with some loss of vision or irreversible blindness has been reported with the use of selective phosphodiesterase type-5 inhibitors including sildenafil (contained in **Sildojub**). NAION appears to be a class effect of these medicines. Most of these patients had risk factors such as low cup to disc ratio ("crowded disk"), age over 50, diabetes, hypertension, coronary artery disease, hyperlipidaemia and smoking. **Sildojub** should not be given to these patients.
- A sudden or bilateral decrease or loss of hearing (sensorineural deafness), with or without associated vestibular symptoms has been reported with the use of PDE5 inhibitors, including **Sildojub**. There is insufficient information regarding the reversibility of the hearing loss and the role of underlying risk factors for hearing loss in individual subjects.
- A large-scale epidemiological study found evidence of an increased risk of retinal detachment with regular use of PDE5 inhibitors.

**Information for patients:**

The use of **Sildojub** offers no protection against sexually transmitted diseases. Counseling of patients about protective measures necessary to guard against sexually transmitted diseases, including the human immunodeficiency virus (HIV/AIDS), should be considered.

Precautions against unwanted pregnancy should be taken.

Sign:



1.3.1.1  
12/May/2025

Page 6 of 17

**Applicant:** Jubilant Pharma SA (Pty) Ltd.

MODULE 1

**Product Name:**

SILDOJUB 25 mg

SILDOJUB 50 mg

SILDOJUB 100 mg

**Dosage form and strength:**

Each film coated tablet contains sildenafil citrate equivalent to 25 mg sildenafil

Each film coated tablet contains sildenafil citrate equivalent to 50 mg sildenafil

Each film coated tablet contains sildenafil citrate equivalent to 100 mg sildenafil

1.3.1.1

**Amendment date:** 12 May 2025

**Lactose monohydrate:**

**Sildojub** contains lactose monohydrate (**see section 2**). Patients with rare hereditary problems of galactose intolerance, the Lapp-lactase deficiency or glucose-galactose malabsorption should not take **Sildojub**.

**4.5 Interaction with other medicines and other forms of interaction**

**Effects of other medicines on Sildojub:**

*In vivo studies:*


A 100 mg single dose of **Sildojub** co-administered with erythromycin 500 mg twice daily, resulted in a 182 % increase in sildenafil systemic exposure (AUC) at steady state. However, with co-administration of sildenafil with azithromycin (500 mg daily for three days), no evidence was found of an effect on the AUC or other kinetic parameters of sildenafil.

Co-administration of a 100 mg single dose of **Sildojub** with saquinavir (1 200 mg three times daily) or ritonavir (500 mg twice daily) resulted respectively in a 210 % and 1 000 % increase in the AUC of sildenafil. (**Sildojub** had no effect on either the saquinavir or ritonavir pharmacokinetics.)

Inhibitors of cytochrome P450 (CYP) isoforms 3A4 (major route of sildenafil) and 2C9 (minor route of sildenafil) isoenzymes may reduce sildenafil clearance which include the following: Cimetidine, erythromycin, itraconazole, ketoconazole and HIV-protease inhibitors, such as saquinavir.

Inducers of cytochrome P450 (CYP) isoform 3A4 may increase the metabolism and clearance of sildenafil, such as rifampicin.

Ritonavir increases the plasma concentration of sildenafil significantly and such combinations should not be given (**see section 4.3**).

Sign: 

1.3.1.1  
12/May/2025

Page 7 of 17

**Applicant:** Jubilant Pharma SA (Pty) Ltd.

MODULE 1

**Product Name:**

**Dosage form and strength:**

1.3.1.1

SILDOJUB 25 mg

Each film coated tablet contains sildenafil citrate equivalent to 25 mg sildenafil

SILDOJUB 50 mg

Each film coated tablet contains sildenafil citrate equivalent to 50 mg sildenafil

SILDOJUB 100 mg

Each film coated tablet contains sildenafil citrate equivalent to 100 mg sildenafil

**Amendment date:** 12 May 2025

No effect of concomitant medication on sildenafil pharmacokinetics acting as CYP2C9 inhibitors (such as tolbutamide, warfarin), CYP2D6 inhibitors (such as selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants), thiazide and related diuretics, loop and potassium sparing diuretics, angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers, beta-adrenoreceptor antagonists or inducers of CYP450 metabolism (such as rifampicin, barbiturates) has been noted.

**Effects of Sildojub on other medicines:**

Sildenafil may potentiate the hypotensive effect of acute and chronic nitrates. Therefore, the concomitant use of **Sildojub** and nitrates or nitric oxide donors is contraindicated (**see section 4.3**).


Concomitant use of **Sildojub** and other antihypertensive medicines may potentiate the antihypertensive effect of these medicines. Symptomatic postural hypotension has been reported in patients who receive concomitant therapy with doxazosin and **Sildojub**. This includes reports of dizziness and light-headedness, but not syncope.

**Sildojub** did not potentiate the increase in bleeding time caused by aspirin. No significant interactions were shown between **Sildojub** and tolbutamide (250 mg) or warfarin (40 mg), both being metabolised by CYP2C9 isoenzyme.

**Sildojub** did not potentiate the hypotensive effects of alcohol in healthy volunteers with mean maximum blood alcohol levels of 80 mg/dl.

Symptomatic hypotension may occur when **Sildojub** is administered concomitantly with alpha-blockers (**see section 4.4**).

**4.6 Fertility, pregnancy and lactation**

Sign: 

1.3.1.1  
12/May/2025

Page 8 of 17

**Applicant:** Jubilant Pharma SA (Pty) Ltd.

MODULE 1

**Product Name:**

SILDOJUB 25 mg

SILDOJUB 50 mg

SILDOJUB 100 mg

**Dosage form and strength:**

Each film coated tablet contains sildenafil citrate equivalent to 25 mg sildenafil

Each film coated tablet contains sildenafil citrate equivalent to 50 mg sildenafil

Each film coated tablet contains sildenafil citrate equivalent to 100 mg sildenafil

1.3.1.1

**Amendment date:** 12 May 2025

**Sildojub** is not indicated for use in women.

Sildenafil was not found to be teratogenic, embryotoxic or foetotoxic in animal studies. Single 100 mg oral doses of sildenafil does not impair sperm motility or morphology.

#### 4.7 Effects on ability to drive and use machines

**Sildojub** can lead to dizziness and altered vision and patients should be aware how they react to **Sildojub** and exercise caution before driving a vehicle, operating hazardous machinery or performing hazardous tasks.

#### 4.8 Undesirable effects

##### **Infections and infestations:**

*Less frequent:* Infection, herpes simplex, cellulitis

##### **Blood and the lymphatic system disorders:**

*Less frequent:* Anaemia and leucopenia

##### **Immune system disorders:**

*Less frequent:* Allergic reaction, hypersensitivity reaction

##### **Metabolism and nutrition disorders:**

*Less frequent:* Thirst, gout, unstable diabetes, hyperglycaemia, hyperuricaemia, hypoglycaemic reaction and hypernatraemia

##### **Psychiatric disorders:**

Sign:



1.3.1.1  
12/May/2025

Page 9 of 17

**Applicant:** Jubilant Pharma SA (Pty) Ltd.

MODULE 1

**Product Name:**

SILDOJUB 25 mg

SILDOJUB 50 mg

SILDOJUB 100 mg

**Dosage form and strength:**

Each film coated tablet contains sildenafil citrate equivalent to 25 mg sildenafil

Each film coated tablet contains sildenafil citrate equivalent to 50 mg sildenafil

Each film coated tablet contains sildenafil citrate equivalent to 100 mg sildenafil

1.3.1.1

**Amendment date:** 12 May 2025

*Frequent:* Insomnia, anxiety

*Less frequent:* Depression, abnormal dreams, anorgasmia

**Nervous system disorders:**

*Frequent:* Headache, dizziness

*Less frequent:* Ataxia, hypertonia, neuralgia, neuropathy, paraesthesia, tremor, somnolence, decreased reflexes, hypaesthesia, migraine, seizures

**Eye disorders:**

*Frequent:* Cyanopsia, eye irritation, eye pain, ocular redness, photophobia, chromatopsia (mild and transient, predominantly colour tinge to vision)

*Less frequent:* Abnormal vision (increased perception of light, blurred vision), bloodshot appearance, ocular burning, ocular swelling or pressure, increased intraocular pressure, retinal vascular disease or bleeding, vitreous detachment/traction and paramacular oedema, conjunctivitis, eye haemorrhage, cataract, dry eyes, non-arteritic anterior ischaemic optic neuropathy (NAION)


*Frequency unknown:* Diplopia, temporary vision loss, decreased vision

**Ear and labyrinth disorders:**

*Frequent:* Vertigo

*Less frequent:* Tinnitus, deafness, ear pain

**Cardiac disorders:**

Sign: 

1.3.1.1  
12/May/2025

Page 10 of 17

**Applicant:** Jubilant Pharma SA (Pty) Ltd.

MODULE 1

**Product Name:**  
SILDOJUB 25 mg

**Dosage form and strength:**

1.3.1.1

SILDOJUB 50 mg

Each film coated tablet contains sildenafil citrate equivalent to 25 mg sildenafil

SILDOJUB 100 mg

Each film coated tablet contains sildenafil citrate equivalent to 50 mg sildenafil

Each film coated tablet contains sildenafil citrate equivalent to 100 mg sildenafil

**Amendment date:** 12 May 2025

*Frequent:* Palpitations

*Less frequent:* Serious cardiovascular events, myocardial infarction, sudden cardiac death, ventricular dysrhythmia, angina pectoris, AV block, tachycardia, cardiac arrest, heart failure, abnormal electrocardiogram, cardiomyopathy

**Vascular disorders:**

*Frequent:* Epistaxis

*Less frequent:* Cerebrovascular haemorrhage, transient ischaemic attack, hypertension (see section 4.4) hypotension, postural hypotension, vasodilatation (flushing), shock

**Respiratory, thoracic and mediastinal disorders:**

*Frequent:* Nasal congestion, dyspnoea

*Less frequent:* Asthma, laryngitis, pharyngitis, sinusitis, bronchitis, increased sputum, increased cough, respiratory disorder, respiratory tract infection

**Gastrointestinal disorders:**

*Frequent:* Dyspepsia, diarrhoea, nausea, vomiting

*Less frequent:* Abdominal pain, glossitis, colitis, dysphagia, gastritis, gastroenteritis, oesophagitis, stomatitis, dry mouth, rectal haemorrhage, gingivitis

**Skin and subcutaneous tissue disorders:**

*Frequent:* Flushing, erythema

*Less frequent:* Urticaria, pruritus, sweating, skin ulcer, contact dermatitis, exfoliative dermatitis, rash, photosensitivity reaction

Sign:



1.3.1.1  
12/May/2025

Page 11 of 17

**Applicant:** Jubilant Pharma SA (Pty) Ltd.

MODULE 1

**Product Name:**  
SILDOJUB 25 mg

**Dosage form and strength:**

1.3.1.1

SILDOJUB 50 mg

Each film coated tablet contains sildenafil citrate equivalent to 25 mg sildenafil

SILDOJUB 100 mg

Each film coated tablet contains sildenafil citrate equivalent to 50 mg sildenafil

Each film coated tablet contains sildenafil citrate equivalent to 100 mg sildenafil

**Amendment date:** 12 May 2025

**Musculoskeletal, connective tissue and bone disorders:**

*Less frequent:* Arthritis, arthrosis, tendon rupture, tenosynovitis, myasthenia, synovitis, arthralgia, back pain, bone pain, myalgia

**Renal and urinary disorders:**

*Less frequent:* Cystitis, nocturia, urinary frequency, urinary incontinence, haematuria

**Reproductive system and breast disorders:**

*Less frequent:* Priapism (prolonged erection), breast enlargement, abnormal ejaculation, genital oedema, prostatic disorder

**General disorders and administrative site conditions:**

*Frequent:* Pyrexia (fever)


*Less frequent:* Facial oedema, asthenia, pain, chills, accidental fall, chest pain, accidental injury, oedema, peripheral oedema, syncope

**Investigations:**

*Less frequent:* Abnormal liver function tests, abnormal electrocardiogram (ECG)

*Reporting of suspected adverse reactions*

Reporting suspected adverse reactions after authorisation of SILDOJUB is important. It allows continued monitoring of the benefit/risk balance of SILDOJUB. Health care providers are asked to report any suspected adverse reactions to SAHPRA via Med Safety APP (Medsafety X SAHPRA)

Sign: 

1.3.1.1  
12/May/2025

Page 12 of 17

**Applicant:** Jubilant Pharma SA (Pty) Ltd.

MODULE 1

**Product Name:**

**Dosage form and strength:**

1.3.1.1

SILDOJUB 25 mg

Each film coated tablet contains sildenafil citrate equivalent to 25 mg sildenafil

SILDOJUB 50 mg

Each film coated tablet contains sildenafil citrate equivalent to 50 mg sildenafil

SILDOJUB 100 mg

Each film coated tablet contains sildenafil citrate equivalent to 100 mg sildenafil

**Amendment date:** 12 May 2025

and eReporting platform (who- umc.org) found on the SAHPRA website. By reporting side effects, you can help provide more information on the safety of SILDOJUB.

#### 4.9 Overdose

Symptomatic or supportive measures should be adopted as required, in the event of an overdose.

Renal dialysis is not expected to accelerate clearance as sildenafil is highly bound to plasma proteins and not eliminated in the urine.

### 5. PHARMACOLOGICAL PROPERTIES

#### 5.1 Pharmacodynamic properties

##### A 7.1.5 Vasodilators – peripheral


Sildenafil is a selective phosphodiesterase type 5 (PDE5) inhibitor, an enzyme responsible for degrading cyclic guanosine monophosphate (cGMP) in the corpus cavernosum. Sildenafil enhances the effect of nitric oxide (NO) on the corpus cavernosum tissue during sexual stimulation, resulting in increased cGMP levels, causing the smooth muscle to relax, allowing blood flow into the corpus cavernosum producing an erection. Without sexual stimulation, sildenafil has no effect on erections. Sildenafil increases blood flow to the penis, in response to sexual stimulation and thereby restores impaired erectile function.

#### 5.2 Pharmacokinetic properties

##### **Absorption:**

Sildenafil is well absorbed after an oral dose with a mean absolute bioavailability of about 40 %.

Peak plasma concentrations are reached within 30 to 120 minutes (median 60 minutes) of oral dosing in the fasted state. The oral pharmacokinetics of sildenafil is proportional over the

Sign: 

1.3.1.1  
12/May/2025

Page 13 of 17

**Applicant:** Jubilant Pharma SA (Pty) Ltd.

MODULE 1

**Product Name:**

**Dosage form and strength:**

1.3.1.1

SILDOJUB 25 mg

Each film coated tablet contains sildenafil citrate equivalent to 25 mg sildenafil

SILDOJUB 50 mg

Each film coated tablet contains sildenafil citrate equivalent to 50 mg sildenafil

SILDOJUB 100 mg

Each film coated tablet contains sildenafil citrate equivalent to 100 mg sildenafil

**Amendment date:** 12 May 2025

recommended dose range (25 - 100 mg).

A high fat meal reduces absorption of sildenafil as shown by a mean reduction in the maximum plasma concentration ( $C_{max}$ ) of 29 % and a mean delay in the time to peak concentration ( $T_{max}$ ) of 60 minutes.

***Distribution:***

The mean steady state volume of distribution ( $V_{ss}$ ) for sildenafil is 105 litres. Sildenafil and its major circulating *N*-desmethyl metabolite, exhibit high (96 %) plasma protein binding, independent of total medicine concentrations.

Less than 0,0002 % of sildenafil remained in the semen of healthy volunteers at 90 minutes after dosing.

***Metabolism:***


Hepatic metabolism of sildenafil is predominantly by the CYP3A4 (major route) and CYP2C9 (minor route) microsomal isoenzymes. Sildenafil is converted by *N*-demethylation to an active metabolite with a PDE selectivity profile similar to sildenafil. The terminal half-life of the *N*-desmethyl metabolite is approximately 4 hours.

***Elimination:***

Sildenafil is excreted as metabolites mainly in the faeces (approximately 80 % of administered oral dose) and to a lesser extent in the urine (approximately 13 % of administered oral dose).

**Pharmacokinetics in special patient groups:**

***Elderly:***

Sign: 

1.3.1.1  
12/May/2025

Page 14 of 17

**Applicant:** Jubilant Pharma SA (Pty) Ltd.

MODULE 1

**Product Name:**

SILDOJUB 25 mg

SILDOJUB 50 mg

SILDOJUB 100 mg

**Dosage form and strength:**

Each film coated tablet contains sildenafil citrate equivalent to 25 mg sildenafil

Each film coated tablet contains sildenafil citrate equivalent to 50 mg sildenafil

Each film coated tablet contains sildenafil citrate equivalent to 100 mg sildenafil

1.3.1.1

**Amendment date:** 12 May 2025

Healthy elderly volunteers, 65 years or over, cleared sildenafil less effectively from the plasma than did normal healthy volunteers, 18 to 45 years of age, as shown by a 40 % increase of AUC in older adults.

***Renal insufficiency:***

Sildenafil clearance was reduced in volunteers with severe renal impairment, with creatinine clearance values of  $CL_{Cr} \leq 30$  ml/min, resulting in increases in AUC (100 %) and  $C_{max}$  (88 %) compared to age-matched volunteers with no renal impairment (**see section 4.2**). The pharmacokinetics of sildenafil were not altered in persons with mild to moderate renal impairment.

***Hepatic insufficiency:***

Sildenafil clearance was reduced in volunteers with hepatic cirrhosis (Child-Pugh A and B), resulting in increases in AUC by 84 % and  $C_{max}$  by 47 % compared to age-matched volunteers with no hepatic impairment (**see section 4.2**).

## 6. PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

Anhydrous calcium hydrogen phosphate, croscarmellose sodium, magnesium stearate, microcrystalline cellulose and Opadry White (containing hypromellose, lactose monohydrate, titanium dioxide and triacetin).

Contains sugar: lactose monohydrate.

### 6.2 Incompatibilities

Not applicable.

Sign:



1.3.1.1  
12/May/2025

Page 15 of 17

**Applicant:** Jubilant Pharma SA (Pty) Ltd.

MODULE 1

**Product Name:**

1.3.1.1

SILDOJUB 25 mg

**Dosage form and strength:**

Each film coated tablet contains sildenafil citrate equivalent to 25 mg sildenafil

SILDOJUB 50 mg

Each film coated tablet contains sildenafil citrate equivalent to 50 mg sildenafil

SILDOJUB 100 mg

Each film coated tablet contains sildenafil citrate equivalent to 100 mg sildenafil

**Amendment date:** 12 May 2025

### 6.3 Shelf life

36 months

### 6.4 Special precautions for storage

Store at or below 25 °C.

Do not remove blister strips from outer carton until required for use.

**KEEP OUT OF REACH OF CHILDREN.**

### 6.5 Nature and contents of container

**Sildojub 25 mg:** Aluminium foil/transparent PVC film blister strips containing 2 or 4 tablets packed into an outer carton. Pack sizes: 2, 4 or 12 tablets.

**Sildojub 50 mg:** Aluminium foil/transparent PVC film blister strips containing 2 or 4 tablets packed into an outer carton. Pack sizes: 2, 4 or 12 tablets.

**Sildojub 100 mg:** Aluminium foil/transparent PVC film blister strips containing 2 or 4 tablets packed into an outer carton. Pack sizes: 2, 4 or 12 tablets.

### 6.6 Special precautions for disposal


No special requirements.

## 7. HOLDER OF CERTIFICATE OF REGISTRATION

**Jubilant Pharma SA (Pty) Ltd.**

24 Parrot Avenue

Extension 1, Lenasia

Sign: 

1.3.1.1  
12/May/2025

Page 16 of 17

**Applicant:** Jubilant Pharma SA (Pty) Ltd.

MODULE 1

**Product Name:**

1.3.1.1

SILDOJUB 25 mg

**Dosage form and strength:**

Each film coated tablet contains sildenafil citrate equivalent to 25 mg sildenafil

SILDOJUB 50 mg

Each film coated tablet contains sildenafil citrate equivalent to 50 mg sildenafil

SILDOJUB 100 mg

Each film coated tablet contains sildenafil citrate equivalent to 100 mg sildenafil

**Amendment date:** 12 May 2025

Johannesburg, 1820,

Gauteng

Contact Details: [g-rp.sa@jubl.com](mailto:g-rp.sa@jubl.com)

## 8. REGISTRATION NUMBERS

**Sildojub 25 mg:** 45/7.1.5/0735

**Sildojub 50 mg:** 45/7.1.5/0736

**Sildojub 100 mg:** 45/7.1.5/0737

## 9. DATE OF FIRST AUTHORISATION


27 November 2014

## 10. DATE OF REVISION OF THE TEXT

30 April 2025

## DATE OF PUBLICATION OF THIS PACKAGE INSERT

20 October 2022

Sign: 

1.3.1.1  
12/May/2025

Page 17 of 17